Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jeffrey Cummings

Showing results (1-10 of 243) with videos related to

Pageof 25
Sort By:
Clinical and Translational Science|August 3, 2017
Lessons Learned from Alzheimer Disease: Clinical Trials with Negative OutcomesJeffrey Cummings
Drugs|April 15, 2023
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease TherapeuticsJeffrey Cummings
Molecular Neurodegeneration|April 2, 2021
Correction to: New approaches to symptomatic treatments for Alzheimer's diseaseJeffrey Cummings
International Psychogeriatrics|May 3, 2023
Rarer dementias, limited options, and unaddressed needsJeffrey Cummings
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|August 22, 2020
The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative DiseasesJeffrey Cummings
Journal of Alzheimer'S Disease : JAD|March 22, 2024
"Landscape of Phase 2 Trials in Alzheimer's Disease": Perspective on Adaptive TrialsJeffrey Cummings
Nature Reviews. Neurology|November 26, 2021
Disease modification is not all - we need symptomatic therapies for Alzheimer diseaseJeffrey Cummings
Molecular Neurodegeneration|January 14, 2021
New approaches to symptomatic treatments for Alzheimer's diseaseJeffrey Cummings
Alzheimer'S & Dementia (New York, N. Y.)|March 11, 2025
Perspective: Minimal clinically important difference (MCID) and Alzheimer's disease clinical trialsJeffrey Cummings
Journal of Geriatric Psychiatry and Neurology|February 5, 2020
The Neuropsychiatric Inventory: Development and ApplicationsJeffrey Cummings
Pageof 25

Showing results (1-10 of 243) with videos related to

Sort By:
Pageof 25
Clinical and Translational Science|August 3, 2017
Lessons Learned from Alzheimer Disease: Clinical Trials with Negative OutcomesJeffrey Cummings
Drugs|April 15, 2023
Anti-Amyloid Monoclonal Antibodies are Transformative Treatments that Redefine Alzheimer's Disease TherapeuticsJeffrey Cummings
Molecular Neurodegeneration|April 2, 2021
Correction to: New approaches to symptomatic treatments for Alzheimer's diseaseJeffrey Cummings
International Psychogeriatrics|May 3, 2023
Rarer dementias, limited options, and unaddressed needsJeffrey Cummings
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|August 22, 2020
The Role of Neuropsychiatric Symptoms in Research Diagnostic Criteria for Neurodegenerative DiseasesJeffrey Cummings
Journal of Alzheimer'S Disease : JAD|March 22, 2024
"Landscape of Phase 2 Trials in Alzheimer's Disease": Perspective on Adaptive TrialsJeffrey Cummings
Nature Reviews. Neurology|November 26, 2021
Disease modification is not all - we need symptomatic therapies for Alzheimer diseaseJeffrey Cummings
Molecular Neurodegeneration|January 14, 2021
New approaches to symptomatic treatments for Alzheimer's diseaseJeffrey Cummings
Alzheimer'S & Dementia (New York, N. Y.)|March 11, 2025
Perspective: Minimal clinically important difference (MCID) and Alzheimer's disease clinical trialsJeffrey Cummings
Journal of Geriatric Psychiatry and Neurology|February 5, 2020
The Neuropsychiatric Inventory: Development and ApplicationsJeffrey Cummings
Pageof 25